论文部分内容阅读
许多肿瘤细胞表面表皮生长因子受体EGFR都存在过表达现象。考察了牛痘病毒生长因子(VGF)中的EGFR结合域(S3)与人的肝素样表皮生长因子(HB-EGF)来源的肝素结合域(命名为HE)重组后对肿瘤细胞的选择性。通过重组表达带有靶向和穿膜结构域的EGFP-S3-HE和EGFP-S3-HE-TATm两种融合蛋白与正常细胞和肿瘤细胞的共孵育实验来研究其对肿瘤细胞的特异性靶向吸附和穿膜效应。进一步将S3-HE-TATm靶向穿膜序列与苦瓜来源的核糖体失活蛋白MAP30融合,可显著提高MAP30对肿瘤细胞的抑杀作用,但这种抑杀作用却对正常细胞仍保持在较低水平。由此表明S3-HE-TATm是一种新型优异的肿瘤细胞靶向药物运输载体,可用于肿瘤治疗的进一步开发研究。
Many tumor cell surface epidermal growth factor receptor EGFR overexpression. The selectivity for tumor cells after recombination of the EGFR binding domain (S3) in vaccinia virus growth factor (VGF) with the human heparin-like epidermal growth factor (HB-EGF) derived heparin binding domain (named HE) was examined. Targeted and transmembrane domain-specific EGFP-S3-HE and EGFP-S3-HE-TATm fusion proteins were co-incubated with normal cells and tumor cells to study their specific targets on tumor cells Adsorption and transmembrane effects. Further targeting S3-HE-TATm transmembrane sequence fusion with bitter melon-derived ribosomal inactivation protein MAP30 can significantly increase the inhibitory effect of MAP30 on tumor cells, but this inhibitory effect on normal cells is still maintained at a relatively Low level. Thus, S3-HE-TATm is a novel and excellent tumor cell-targeted drug delivery carrier that can be used for further development of cancer therapy.